ADAR1 Capital Management LLC Takes $305,000 Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)

ADAR1 Capital Management LLC purchased a new stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 106,000 shares of the company’s stock, valued at approximately $305,000.

A number of other institutional investors have also recently made changes to their positions in LPTX. Geode Capital Management LLC boosted its stake in Leap Therapeutics by 18.0% during the third quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock worth $847,000 after buying an additional 50,194 shares during the period. HighTower Advisors LLC purchased a new position in shares of Leap Therapeutics during the 3rd quarter worth about $65,000. HB Wealth Management LLC boosted its stake in shares of Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after purchasing an additional 26,150 shares during the period. Monaco Asset Management SAM bought a new position in Leap Therapeutics during the 4th quarter valued at about $592,000. Finally, Key Client Fiduciary Advisors LLC raised its position in Leap Therapeutics by 12.2% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after purchasing an additional 39,330 shares during the period. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Price Performance

Leap Therapeutics stock opened at $0.29 on Tuesday. The stock has a market cap of $12.06 million, a price-to-earnings ratio of -0.15 and a beta of 0.22. The firm has a 50-day moving average of $0.45 and a two-hundred day moving average of $2.05. Leap Therapeutics, Inc. has a 1 year low of $0.22 and a 1 year high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. Research analysts expect that Leap Therapeutics, Inc. will post -1.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on LPTX shares. HC Wainwright reaffirmed a “neutral” rating on shares of Leap Therapeutics in a research note on Thursday, March 27th. Robert W. Baird cut Leap Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $9.00 to $1.25 in a report on Wednesday, January 29th. Finally, Baird R W lowered Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.